The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...

Merck & Co. is acquiring Verona Pharma PLC in a $10 billion deal that will expand the pharmaceutical giant’s portfolio of ...

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Global markets have been seesawing this week, as traders digest the latest trade tariff news. Overnight, Asia-Pacific markets ...

Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's ...

Verona Pharma brings to Merck the inhaled drug Ohtuvayre, which is FDA approved as a treatment for chronic obstructive ...

Merck ( NYSE: MRK) has confirmed a deal worth around $10 billion to acquire Verona Pharma ( NASDAQ: VRNA ), a biotech firm ...

Merck is expanding its pipeline and portfolio of cardio-pulmonary disease treatments by acquiring Verona Pharma plc.

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma giant’s pipeline and portfolio of cardio-pulmonary disease treatments.

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

Merck, through a subsidiary, will acquire Verona Pharma for a total transaction value of approximately $10 billion.